E. A. Kiseleva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
E. A. Kiseleva has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Tatiana G. Smirnova
Central Tuberculosis Research Institute, Moscow, Russia
3 shared publications - Atadzhan E. Ergeshov
Central Tuberculosis Research Institute
2 shared publications - E. E. Larionova
Central Tuberculosis Research Institute
2 shared publications - Sofya N. Andreevskaya
Central Tuberculosis Research Institute, Moscow, Russia
2 shared publications A Ergeshov
Central Tuberculosis Research Institute, Moscow, Russia
1 shared publication- Elena S. Ovsyankina
Central Research Institute of Tuberculosis
1 shared publication
Latest Publications
- 30 October 2025
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 70 (9-10)
Frequency of Resistance to Delamanid in Mycobacterium tuberculosis Isolated from Patients with Pulmonary Tuberculosis in the Russian Federation
Delamanid is one of the key new drugs for the treatment of multidrug-resistant and, in particular, extensively drug-resistant tuberculosis. However, due to its relatively recent introduction into clinical practice, data on the frequencу of resistance detection to this drug remain limited. The aim of the study was to determine the phenotypic susceptibility of Mycobacterium tuberculosis , isolated from patients with pulmonary tuberculosis in the Russian Federation, to delamanid. Materials and methods. The study included a total of 271 M. tuberculosis isolates with different resistance pat terns, obtained from patients in the Russian Federation (2022–2025). Resistance to delamanid (pure substance, Otsuka Pharmaceutical Co., Ltd., Japan) was determined using a modified proportional assay in the BACTEC MGIT 960 system; the critical concentration for delamanid was 0.06 µg/mL. Results . Resistance to delamanid was detected in 14.39% (39/271) of cases in both M. tuberculosis isolates susceptible to other anti-tuberculosis drugs and M. tuberculosis isolates with resistance profiles including 1 to 10 drugs (excluding delamanid). The incidence of delamanid resistance in M. tuberculosis with retained susceptibility to rifampin and in M. tuberculosis with multidrug/extensive drug resistance did not differ significantly, amounting to 11.49% and 15.76%, respectively. Primary resistance to delamanid was detected in at least 3.69% (10/271) of the cases. Conclusion. The data obtained indicate a significant level of resistance to delamanid, including among isolates not exposed to the drug. Therefore, it is imperative to improve measures to control the spread of pathogens resistant to this antimicrobial agent.
- 30 October 2025
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 70 (9-10)
Frequency of Resistance to Delamanid in Mycobacterium tuberculosis Isolated from Patients with Pulmonary Tuberculosis in the Russian Federation
Delamanid is one of the key new drugs for the treatment of multidrug-resistant and, in particular, extensively drug-resistant tuberculosis. However, due to its relatively recent introduction into clinical practice, data on the frequencу of resistance detection to this drug remain limited. The aim of the study was to determine the phenotypic susceptibility of Mycobacterium tuberculosis , isolated from patients with pulmonary tuberculosis in the Russian Federation, to delamanid. Materials and methods. The study included a total of 271 M. tuberculosis isolates with different resistance pat terns, obtained from patients in the Russian Federation (2022–2025). Resistance to delamanid (pure substance, Otsuka Pharmaceutical Co., Ltd., Japan) was determined using a modified proportional assay in the BACTEC MGIT 960 system; the critical concentration for delamanid was 0.06 µg/mL. Results . Resistance to delamanid was detected in 14.39% (39/271) of cases in both M. tuberculosis isolates susceptible to other anti-tuberculosis drugs and M. tuberculosis isolates with resistance profiles including 1 to 10 drugs (excluding delamanid). The incidence of delamanid resistance in M. tuberculosis with retained susceptibility to rifampin and in M. tuberculosis with multidrug/extensive drug resistance did not differ significantly, amounting to 11.49% and 15.76%, respectively. Primary resistance to delamanid was detected in at least 3.69% (10/271) of the cases. Conclusion. The data obtained indicate a significant level of resistance to delamanid, including among isolates not exposed to the drug. Therefore, it is imperative to improve measures to control the spread of pathogens resistant to this antimicrobial agent.
- Open Access
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (3)
Cellular and humoral responses to SARS-CoV-2 (omicron variant) in children and adolescents with pulmonary tuberculosis
Клеточный и гуморальный ответ на SARS-CoV-2 (штамм омикрон) у детей и подростков с туберкулезом органов дыхания
- 1 January 2023
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 44 (3)
Open AccessCellular and humoral responses to SARS-CoV-2 (omicron variant) in children and adolescents with pulmonary tuberculosis
Клеточный и гуморальный ответ на SARS-CoV-2 (штамм омикрон) у детей и подростков с туберкулезом органов дыхания
- 31 October 2022
- Published by Pirogov Russian National Research Medical University in Bulletin of Russian State Medical University
- No. 2022(5)
The nature of genotypic resistance to fluoroquinolones in Mycobacterium tuberculosis circulating in Russian Federation
Fluoroquinolones are the main group of drugs used for treatment of multidrug resistant tuberculosis (MDR-TB). The study was aimed to assess the diversity of mutation in the gyrA gene and to evaluate the association of gyrA mutations with the phenotypic resistance to levofloxacin and the general drug resistance profile of the pathogen. The study involved assessment of diagnostic materials obtained from 2836 patients with pulmonary tuberculosis. TB-BIOCHIP-2 and AmplitubeFQ-RV kits were used for identification of the gyrA mutations. Phenotypic drug susceptibility of M. tuberculosis (MTB) was defined using the BACTEC MGIT 960 test system. It was shown that mutations D94G (41.63%; 95% CI: 38.03–45.32%) and A90V (21.32%; 95% CI: 18.44–24.50%) prevailed in MBT, although some isolates carrying these mutations were obtained from the newly diagnosed patients with pulmonary tuberculosis. It was found that mutation D94A was not strongly associated with the phenotypic resistance to fluoroquinolones. Fluoroquinolone resistance was usually associated with multiple drug resistance (93.52%; 95% CI 91.43–95.12%). In 2.31% (95% CI 1.78–3.00%) of cases, genotypic heteroresistance to fluoroquinolones was detected: mixed populations included 2–4 MTB pools with various structure of the gyrA QRDR. The results obtained lead to the conclusion that resistance to fluoroquinolones that is usually associated with the existing MDR arises in the modern MTB population. MTB carrying gyrA mutations D94G and A90V seems to be the most promising in evolutionary terms.
- 31 October 2022
- Published by Pirogov Russian National Research Medical University in Bulletin of Russian State Medical University
- No. 2022(5)
The nature of genotypic resistance to fluoroquinolones in Mycobacterium tuberculosis circulating in Russian Federation
Fluoroquinolones are the main group of drugs used for treatment of multidrug resistant tuberculosis (MDR-TB). The study was aimed to assess the diversity of mutation in the gyrA gene and to evaluate the association of gyrA mutations with the phenotypic resistance to levofloxacin and the general drug resistance profile of the pathogen. The study involved assessment of diagnostic materials obtained from 2836 patients with pulmonary tuberculosis. TB-BIOCHIP-2 and AmplitubeFQ-RV kits were used for identification of the gyrA mutations. Phenotypic drug susceptibility of M. tuberculosis (MTB) was defined using the BACTEC MGIT 960 test system. It was shown that mutations D94G (41.63%; 95% CI: 38.03–45.32%) and A90V (21.32%; 95% CI: 18.44–24.50%) prevailed in MBT, although some isolates carrying these mutations were obtained from the newly diagnosed patients with pulmonary tuberculosis. It was found that mutation D94A was not strongly associated with the phenotypic resistance to fluoroquinolones. Fluoroquinolone resistance was usually associated with multiple drug resistance (93.52%; 95% CI 91.43–95.12%). In 2.31% (95% CI 1.78–3.00%) of cases, genotypic heteroresistance to fluoroquinolones was detected: mixed populations included 2–4 MTB pools with various structure of the gyrA QRDR. The results obtained lead to the conclusion that resistance to fluoroquinolones that is usually associated with the existing MDR arises in the modern MTB population. MTB carrying gyrA mutations D94G and A90V seems to be the most promising in evolutionary terms.